Kadans Science Partner today welcomes Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, to its Building M at the Novio Tech Campus, a state-of-the-art health and life sciences research facility in Nijmegen, the Netherlands.

The facility will act as the new corporate headquarters for Khondrion’s operations, providing the Company with the necessary capacity to support its growth plans as it continues to develop its novel, potential first-in-class therapy, sonlicromanol, for mitochondrial diseases.

The Novio Tech Campus is a hub for health and high-tech companies, encouraging open innovation between researchers and entrepreneurs. With 75 companies, employing more than 3,400 people, the dynamic environment and extensive network provided by the Novio Tech Campus offers many new opportunities for business development and collaboration.

Jan Smeitink, Chief Executive Officer of Khondrion, commented “Moving to the new facilities at the Novio Tech Campus marks a major milestone in Khondrion’s growth and our progress, since launching almost a decade ago, to discover and develop novel therapies targeting mitochondrial disease. Being based in one of the Netherland’s major science hubs will, I hope, provide new opportunities to drive innovation within our labs and enable us to develop the new treatment options for patients living with primary mitochondrial diseases that are long overdue.”

Pim van Os, Commercial Asset Manager at Kadans Science Partner:We are happy to welcome Khondrion to the community at Novio Tech Campus. As a spin-off from from Radboudumc, they are a great addition to the innovative ecosystem. We are looking forward to new connections, new innovations and Khondrion’s further growth.”

Khondrion is focused on developing sonlicromanol, a potentially first-in-class oral small molecule and one of the most clinically advanced disease-modifying drug candidates for primary mitochondrial diseases in development. Sonlicromanol is currently in an ongoing Phase IIb clinical trial in adult patients with MELAS spectrum disorders and a Phase II paediatric study exploring its pharmacokinetics, safety and efficacy in children with a genetically confirmed primary mitochondrial diseases and suffering from motor symptoms.